A reality check of the accelerated approval of immune-checkpoint inhibitors

Jennifer Gill^{1

2}, Vinay Prasad^{3

4

5

6}

Affiliations

¹ Division of Hematology Oncology, Oregon Health & Science University, Portland, OR, USA.
² Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
³ Division of Hematology Oncology, Oregon Health & Science University, Portland, OR, USA. prasad@ohsu.edu.
⁴ Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA. prasad@ohsu.edu.
⁵ Department of Public Health and Preventive Medicine, Oregon Health & Science University, Portland, OR, USA. prasad@ohsu.edu.
⁶ Center for Health Care Ethics, Oregon Health & Science University, Portland, OR, USA. prasad@ohsu.edu.

Jennifer Gill et al. Nat Rev Clin Oncol. 2019 Nov.

. 2019 Nov;16(11):656-658.

doi: 10.1038/s41571-019-0260-y. Epub 2019 Aug 5.

Jennifer Gill^{1

2}, Vinay Prasad^{3

4

5

6}

¹ Division of Hematology Oncology, Oregon Health & Science University, Portland, OR, USA.
² Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
³ Division of Hematology Oncology, Oregon Health & Science University, Portland, OR, USA. prasad@ohsu.edu.
⁴ Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA. prasad@ohsu.edu.
⁵ Department of Public Health and Preventive Medicine, Oregon Health & Science University, Portland, OR, USA. prasad@ohsu.edu.
⁶ Center for Health Care Ethics, Oregon Health & Science University, Portland, OR, USA. prasad@ohsu.edu.

No abstract available

MeSH terms